Literature DB >> 17909738

[Prostate carcinoma].

H-P Schlemmer1.   

Abstract

Prostate cancer is the most common malignancy in men in Europe, North America, and in some African states. Early diagnosis in an asymptomatic stage is possible through the combination of digitorectal examination, PSA serum testing, and systematic biopsy. However, general screening is so far not recommended by the Urologic Societies, because the efficiency is not yet proved. Imaging is also not recommended for first-line screening. Novel functional methods of transrectal ultrasound (TRUS) and endorectal MRI can improve accuracy of tumor detection to more than 90% and can be used for TRUS- and now also MRI-guided biopsy leading to two- to threefold higher tumor detection rates. There is general agreement that all men over 50 years of age should be informed about the possibilities, benefits, and risks of the available methods for early tumor detection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17909738     DOI: 10.1007/s00117-007-1555-z

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  33 in total

1.  MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies.

Authors:  Aristotelis G Anastasiadis; Matthias P Lichy; Udo Nagele; Markus A Kuczyk; Axel S Merseburger; Joerg Hennenlotter; Stefan Corvin; Karl-Dietrich Sievert; Claus D Claussen; Arnulf Stenzl; Heinz-Peter Schlemmer
Journal:  Eur Urol       Date:  2006-03-24       Impact factor: 20.096

Review 2.  [The value of ultrasound (US) in the diagnosis of prostate cancer].

Authors:  F Frauscher; A Klauser; A P Berger; E J Halpern; G Feuchtner; F Koppelstaetter; L Pallwein; G M Pinggera; H Weirich; W Horninger; G Bartsch; D zur Nedden
Journal:  Radiologe       Date:  2003-06       Impact factor: 0.635

3.  Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology.

Authors:  Anno Graser; Andreas Heuck; Bernhard Sommer; Joerg Massmann; Juergen Scheidler; Maximillian Reiser; Ullrich Mueller-Lisse
Journal:  AJR Am J Roentgenol       Date:  2007-01       Impact factor: 3.959

4.  Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection.

Authors:  Stefan A Reinsberg; Geoffrey S Payne; Sophie F Riches; Sue Ashley; Jonathan M Brewster; Veronica A Morgan; Nandita M deSouza
Journal:  AJR Am J Roentgenol       Date:  2007-01       Impact factor: 3.959

5.  High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience.

Authors:  Jeffrey J Hom; Fergus V Coakley; Jeffry P Simko; Ying Lu; Aliya Qayyum; Antonio C A Westphalen; Lars D Schmitt; Peter R Carroll; John Kurhanewicz
Journal:  Radiology       Date:  2006-12-19       Impact factor: 11.105

Review 6.  Prostate cancer: the diagnostic dilemma and the place of imaging in detection and staging.

Authors:  M D Rifkin
Journal:  World J Urol       Date:  1998       Impact factor: 4.226

7.  Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing.

Authors:  Willi Oberaigner; Wolfgang Horninger; Helmut Klocker; Dieter Schönitzer; Wolf Stühlinger; Georg Bartsch
Journal:  Am J Epidemiol       Date:  2006-07-07       Impact factor: 4.897

8.  Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer.

Authors:  Liang Wang; Hedvig Hricak; Michael W Kattan; Lawrence H Schwartz; Steven C Eberhardt; Hui-Ni Chen; Peter T Scardino
Journal:  AJR Am J Roentgenol       Date:  2006-03       Impact factor: 3.959

9.  The significance of isoechoic prostatic carcinoma.

Authors:  W J Ellis; M K Brawer
Journal:  J Urol       Date:  1994-12       Impact factor: 7.450

10.  Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography.

Authors:  W J Ellis; M P Chetner; S D Preston; M K Brawer
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

View more
  4 in total

1.  [Magnetic resonance tomography-guided interventional procedure for diagnosis of prostate cancer].

Authors:  M Schernthaner; T H Helbich; B J Fueger; M Margreiter; M Memarsadeghi; A Stiglbauer; H-G Linhart; A Doan; K Pinker; P Brader
Journal:  Radiologe       Date:  2011-11       Impact factor: 0.635

2.  [Diagnose importance of multiparametric magnetic resonance tomography for prostate cancer].

Authors:  B J Fueger; T H Helbich; M Schernthaner; S Zbýn; H G Linhart; A Stiglbauer; A Doan; K Pinker; G Heinz; A R Padhani; P Brader
Journal:  Radiologe       Date:  2011-11       Impact factor: 0.635

Review 3.  [Irreversible electroporation (IRE) : A minimally invasive therapeutic option in prostate cancer].

Authors:  P Wiggermann; K Brünn; W Bäumler
Journal:  Radiologe       Date:  2017-08       Impact factor: 0.635

4.  ATRA inhibits the proliferation of DU145 prostate cancer cells through reducing the methylation level of HOXB13 gene.

Authors:  Zhiwei Liu; Guoling Ren; Chenyan Shangguan; Lijing Guo; Zhixiong Dong; Yueyang Li; Weina Zhang; Li Zhao; Pingfu Hou; Yu Zhang; Xiuli Wang; Jun Lu; Baiqu Huang
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.